


RealRate

PHARMACEUTICAL 2020

Allergan plc Rank 65 of 362





PHARMACEUTICAL 2020



Allergan plc Rank 65 of 362

The relative strengths and weaknesses of Allergan plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Allergan plc compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 202% points. The greatest weakness of Allergan plc is the variable Other Expenses, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 65%, being 367% points above the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	11,126,700
Cost of Goods Sold	2,493,100
Intangible Assets	80,138,900
Liabilities, Current	11,070,700
Liabilities, Non-Current	1,247,000
Other Assets	1,507,000
Other Compr. Net Income	-143,900
Other Expenses	13,893,700
Other Liabilities	24,185,000
Other Net Income	-673,400
Property and Equipment	1,926,500
Research and Development	1,812,000
Revenues	16,088,900
Selling, General and Administrative Expense	2,481,800

Output Variable	Value in 1000 USD
Assets	94,699,100
Liabilities	36,502,700
Expenses	20,680,600
Stockholders Equity	58,196,400
Net Income	-5,265,100
Comprehensive Net Income	-5,337,050
Economic Capital Ratio	65%